|
WO2021009358A1
|
|
Antibody combinations for treatment of cancer in specific patients
|
|
WO2020089474A1
|
|
Novel antagonistic anti tnfr2 antibody molecules
|
|
WO2020089473A2
|
|
Novel agonistic anti tnfr2 antibody molecules
|
|
EP3617230A1
|
|
Novel antibodies and nucleotide sequences, and uses thereof
|
|
GB201800395D0
|
|
Novel combination and use of antibodies
|
|
US2020362036A1
|
|
Novel combination and use of antibodies
|
|
GB201712032D0
|
|
Antibodies and uses thereof
|
|
AU2015261422A1
|
|
Medicaments, uses and methods
|
|
GB201406311D0
|
|
Biological materials and uses thereof
|
|
US2015352207A1
|
|
Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients
|
|
AU2012216655A1
|
|
Biological materials and uses thereof
|
|
GB201116774D0
|
|
Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
|
|
GB201116364D0
|
|
Screening methods and uses thereof
|
|
GB201112000D0
|
|
Biological materials and uses thereof
|
|
GB201020995D0
|
|
Biological materials and uses thereof
|
|
GB201011771D0
|
|
Biological material and particular uses thereof
|
|
GB201011770D0
|
|
Biological material and there uses thereof
|
|
GB201009307D0
|
|
Biological materials and uses thereof
|
|
GB0903151D0
|
|
Antibody uses and methods
|
|
KR20100110841A
|
|
Formulation
|
